Clincosm LogoSign in Get a demo

Elevated Stearoyl-CoA Desaturase-1 Expression Predicts the Disease Severity of Severe Acute Pancreatitis

Sponsor
Nanjing University School of Medicine (Other)
Overall Status
Unknown status
CT.gov ID
NCT03282253
Collaborator
(none)
216
Enrollment
17.9
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

In this study, the investgatiors aimed to investigate the associations between serum levels of stearoyl-CoA desaturase-1（SCD-1） and the disease severity as well as the presence of adverse clinical events, such as local complications, organ failure, mortality and so on.In this prospective study, participants were divided into two groups based on serum SCD-1 concentration on admission and prospectively observe the disease severity and clinical outcomes of them.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    216 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Elevated Stearoyl-CoA Desaturase-1 Expression Predicts the Disease Severity and Clinical Outcomes of Severe Acute Pancreatitis
    Anticipated Study Start Date :
    Jan 1, 2018
    Anticipated Primary Completion Date :
    Dec 30, 2018
    Anticipated Study Completion Date :
    Jun 30, 2019

    Outcome Measures

    Primary Outcome Measures

    1. the incidence rate of infected pancreatic necrosis [2-4 week after disease onset]

    Secondary Outcome Measures

    1. the incidence rate of organ failure [1-2 week after disease onset]

      the incidence rate of organ failure (transient or persistent)

    2. the incidence rate of local complications [1-2 week after disease onset]

      acute peripancreatic fluid collections, pancreatic pseudocycts, acute necrotic collections and walled-off necrosis

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    1. Diagnosis of acute pancreatitis (Atlanta standard), abdominal pain occurred within one week of admission;

    2. APACHEII score is more than 8 and Ranson score is greater than 3;

    3. Age 18-75;

    4. Obtaining informed consent.

    Exclusion Criteria:

    1. Pregnancy pancreatitis;

    2. Patients with the following disease history: severe cardiac, pulmonary, renal, liver function insufficiency or immunodeficiency disease.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Nanjing University School of Medicine

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Weiqin Li, Director of Department of Surgical Intensive Care Unit, Nanjing University School of Medicine
    ClinicalTrials.gov Identifier:
    NCT03282253
    Other Study ID Numbers:
    • ESCDEPDSSAP
    First Posted:
    Sep 13, 2017
    Last Update Posted:
    Nov 27, 2017
    Last Verified:
    Nov 1, 2017
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Pancreatitis
    Multiple Organ Failure

    Study Results

    No Results Posted as of Nov 27, 2017